BioMarin Completes Amicus Therapeutics Acquisition, Secures $3.4B Credit Facility

SEC 8-K Filing Notice

Company: BioMarin Pharmaceutical Inc. (BMRN) Filing Date: 2026-04-27 Accession Number: 0001193125-26-179243

Items Filed

Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.03: Creation of a Direct Financial Obligation Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

BioMarin Pharmaceutical Inc. announced the completion of its acquisition of Amicus Therapeutics, Inc. The merger was finalized on April 27, 2026, with Amicus becoming a wholly-owned subsidiary of BioMarin. Amicus shareholders received $14.50 per share in cash. To finance the acquisition and related expenses, BioMarin entered into a new credit agreement providing a $3.4 billion senior secured credit facility, comprised of term loan facilities and a revolving credit facility.

Key Takeaways

BioMarin completed the acquisition of Amicus Therapeutics for $14.50 per share in cash.
A new $3.4 billion senior secured credit facility was established to finance the acquisition.
The credit facility includes a $2.0 billion Term Loan B Facility, an $800 million Term Loan A Facility, and a $600 million Revolving Facility.
Existing BioMarin credit agreement was repaid and terminated.
Certain Amicus option holders and restricted stock unit holders received cash payments as part of the merger agreement.

Analysis

The acquisition of Amicus Therapeutics strengthens BioMarin's position in the rare disease market, potentially expanding its product portfolio and pipeline. The significant debt financing reflects BioMarin's commitment to the acquisition and its confidence in the combined entity's future cash flow generation. For investors, this move signals a strategic shift towards growth through acquisition, which could lead to increased revenue and market share but also introduces integration risks and increased financial leverage. Competitors in the rare disease space will likely reassess their strategies in light of this consolidation. The broader pharmaceutical market may see further consolidation as companies seek to expand their portfolios and pipelines.

This post was automatically generated from an SEC 8-K filing.